NasdaqGM - Delayed Quote USD
Aurinia Pharmaceuticals Inc. (AUPH)
Tune into live earnings calls Now streaming directly on quote pages.
8.00
-0.11
(-1.36%)
At close: May 9 at 4:00:00 PM EDT
8.07
+0.07
+(0.87%)
After hours: May 9 at 7:51:11 PM EDT
Key Executives
Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Peter S. Greenleaf M.B.A. | President, CEO & Director | 1.59M | -- | 1970 |
| Mr. Joseph M. Miller CPA | Chief Financial Officer | 866.87k | -- | 1974 |
| Mr. Matthew Maxwell Donley M.B.A. | Chief Operations Officer | 933.95k | -- | 1969 |
| Mr. Stephen P. Robertson | Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer | 799.52k | -- | 1982 |
| Dr. Gregory F. Keenan M.D. | Chief Medical Officer | 779.11k | -- | 1961 |
| Ms. Andrea Levin Christopher | Executive Director of Corporate Communications & Investor Relations | -- | -- | -- |
| Dr. Premchandran Ramiya Ph.D. | Senior Vice President of Manufacturing & Supply Chain | -- | -- | 1961 |
Aurinia Pharmaceuticals Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 130
Description
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Corporate Governance
Aurinia Pharmaceuticals Inc.’s ISS Governance QualityScore as of May 1, 2025 is 2. The pillar scores are Audit: 6; Board: 3; Shareholder Rights: 2; Compensation: 4.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
May 12, 2025 at 12:30 PM UTC
Aurinia Pharmaceuticals Inc. Earnings Date
Recent Events
Related Tickers
TGTX TG Therapeutics, Inc.
33.64
-0.65%
AXSM Axsome Therapeutics, Inc.
107.76
-1.01%
KPTI Karyopharm Therapeutics Inc.
6.01
-2.28%
AGEN Agenus Inc.
2.9100
-4.28%
HRTX Heron Therapeutics, Inc.
2.1100
-2.76%
AVXL Anavex Life Sciences Corp.
8.25
-3.62%
ACAD ACADIA Pharmaceuticals Inc.
17.44
+3.01%
ARDX Ardelyx, Inc.
3.6200
-0.55%
FOLD Amicus Therapeutics, Inc.
5.98
-1.64%
ARWR Arrowhead Pharmaceuticals, Inc.
13.03
-1.66%